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1. Introduction
Liver cancer is one of the major cancers in the world [1]. Hundreds of thousand people are 
diagnosed each year with liver cancer. Unfortunately, liver cancer is the second most com-
mon cause of deaths associated with cancer complications, accounting for more than 70%. 
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer [2]. More than two-
third of patients newly diagnosed with HCC are aged >65 years, and this number is expected 
to increase as the world population ages [3]. Furthermore, there is heterogeneity in the aging 
process, which further contributes to the complexity of treatment decisions [4, 5].
HCC originates from normal hepatocytes. Hepatocytes are the cells forming the parenchymal 
tissue of the liver and make up the majority of liver’s mass. Hepatocytes play a crucial role 
in liver functions [6]. They are involved in many biological processes including the metabo-
lism of carbohydrates and lipids, protein synthesis, and notably body detoxification from 
harmful substances. Important proteins such as serum albumin, prothrombin, transferrin, 
fibrinogen, and complement are generated by hepatocytes. In addition to their main role in 
glycogenesis, hepatocytes make fatty acids from carbohydrates leading to triglyceride syn-
thesis. Hepatocytes are highly involved in lipid metabolism and cholesterol synthesis. The 
detoxifying activity of hepatocytes includes drug metabolism, modification of endogenous 
compounds such as steroids and ammonia. However, hepatocytes might be overwhelmed 
with harmful agents and targeted with many hepatic viruses, leading to liver damage and 
ultimately to HCC [7]. The hepatocytes are commonly used for research in both academia 
and pharmaceutical industry in order to investigate the mechanisms of carcinogenesis, viral 
infections, and drug metabolism. Currently, highly innovative research in epigenetics and 
immunology is taken place in order to explore further liver diseases and develop novel thera-
pies for HCC.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2. Epigenetic of HCC
Epigenetic modifications are crucial in HCC. They arise in the context of known risk factors 
leading to chronic liver disease and concern mostly chemical alterations of DNA and histones. 
DNA methylation is the commonly investigated, showing its relevance in the mechanisms of 
gene silencing. Currently, genome-wide methylation analysis indicates important changes in 
the methylation status of oncogenes, signaling molecules, and suppressor genes [8]. Therefore, 
targeting the epigenome could lead to novel therapies of HCC.
3. Immunogenicity of HCC
Tumor immunogenicity of HCC has been first demonstrated by using autologous tumor 
lysate and dendritic cells for the prevention of recurrence in HCC patients. Subsequently, 
several tumor-associated antigens (SART2, CypB, SART3, AFP p53, MRP3, and hTERT) have 
been identified and characterized in HCC, suggesting the development of highly effective 
immunotherapy [9, 10].
The modulation of immune costimulatory molecules has been also shown to play critical role 
in the pathogenicity of the liver. The costimulatory ligand member B7 is a crucial immune 
checkpoint in HCC [11]. B7-1, B7-2, B7-DC, and B7-H1 are expressed on professional antigen-
presenting cells and regulate T cell activation after the binding with CD28, CTLA-4, or PD-1. 
B7-H3 is expressed in human HCC cells and is associated with tumor aggressiveness and post-
operative recurrence [12]. Apparently, B7-H3 promotes aggression and invasion of HCC by 
targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway [13].
4. Common risk factors for HCC
The major common risk factors for HCC are hepatic virus infection with HBV and HCV. Fatty 
liver disease, related or unrelated to alcohol abuse which frequently lead to liver cirrhosis, is 
the other major condition, increasing the risk for developing HCC (Figure 1).
4.1. Hepatitis B virus (HBV) infection
HBV is one of the most common etiologic factors leading to HCC worldwide. The risk of 
developing HCC is more than 15-fold in patients with HBV chronic infection [2, 14]. In most 
developed countries, around of 10% of HCC is associated with HBV infection which occurs 
through either parental contact with infected blood or sexual transmission. In contrast, other 
geographic regions in the world where HBV is endemic such as sub-Saharan Africa and Asia, 
HBV transmission occurs mainly via perinatal exposure [15, 16].
HBV patients are highly prone to secondary infection with hepatitis D virus (HDV). The HDV 
is dependent on HBV genome products to form its own. Infection with HDV is more frequent 
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in sub-Saharan Africa, Mediterranean regions, and South America [17]. At least eight HDV 
genotypes, geographically distributed in different regions of the globe, have been reported. 
An estimated 20 millions of people are infected with one of HDV genotype. In combination 
with HBV infection, HDV precipitates liver failure and HCC [18]. The best treatment for HDV 
infection is the eradication of HBV through HBV vaccine.
Currently, 10 HBV genotypes have been described. Apparently, HBV-infected patients with 
C and D genotypes develop more frequently liver cirrhosis and HCC than HBV patients, 
Figure 1. Risk factors and current therapies of liver cancer. Hepatocellular carcinoma (HCC) is the most prevalent type of 
liver cancer. A. Hepatocytes, the main liver cells are subjected to harmful conditions (hepatitis virus infections) causing 
hepatitis and frequently leading to cirrhosis and ultimately to HCC. Many treatment options are currently available for 
HCC. B. Gross anatomy and histology of healthy liver and liver diseases related to cirrhosis and HCC.
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infected with the other genotype strains. Furthermore, those patients respond poorly to cur-
rent therapies based on interferon or other antiviral agents [15, 16].
4.2. Hepatitis C virus (HCV) infection
HCV infection is also one of the frequent risk factors in developing HCC in the word. The 
risk of HCC is very high in patients chronically infected with HCV [19]. Coinfection with 
HIV or HBV increased this risk further. The high majority of coinfected patients with either HIV 
or HBV precipitate chronic hepatitis, leading to HCC. Suppression of HCV load by IFN 
therapy, apparently, participates in reducing the onset of HCC [20]. However, concerns 
regarding the impact of HCV direct-acting agents (DAAs) on the incidence of HCC continue 
to be raised in clinic [21]. The potential increased risk of HCC in HCV patients under DAAs 
therapy has been reported [22]. Therefore, interferon therapy should not be discontinued at 
least for HCV patients with high risk of HCC.
4.3. Alcohol abuse
Evidence shows that long-term alcohol use is responsible for alcoholic liver disease (ALD) and 
a high risk of developing HCC [23]. ALD is well characterized; however, little progress has 
been made for its treatment. It is well established that alcohol is highly toxic to hepatocytes. 
By causing continuous cell necrosis, it induces perpetual regeneration of hepatocytes and 
paves the way to carcinogenesis [24]. In addition, alcohol causes liver damage by promoting 
inflammation that precipitates cirrhosis and leads to HCC [23]. The effect of alcohol on liver 
disease is boosted in people with viral hepatitis [25].
4.4. Nonalcoholic steatohepatitis (NASH)
NASH is a condition of fatty liver disease in which liver has abnormal fat accumulation and 
increased inflammation. Although the exact etiology of NASH remains unknown, the risk 
factors include obesity, type II diabetes, and related metabolic dysfunctions. NASH patients 
with no cirrhosis have no increased risk of HCC, indicating that induction of liver cirrhosis 
is a leading cause of HCC. However, the outcome of NASH is much similar as other chronic 
hepatitis such as HCV infection [26]. Although the risk of developing HCC might be lower 
in NASH patients than HCV patients, the severity of HCC and patient survival in both cases 
remain similar.
5. Liver cirrhosis and other risk factors for HCC
The majority of HCCs arise from liver cirrhosis, a condition in which liver tissue is replaced by 
scar tissue [27]. The scar tissue jeopardizes the blood flow through the liver and retains it from 
functioning correctly. Cirrhosis results mainly from different chronic hepatitis mainly due to 
viral infections and fatty liver disease related or unrelated to alcohol abuse. Currently, besides 
HBV, HCV, and HDV, three hepatitis viruses are identified and have been demonstrated to 
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induce hepatitis: hepatitis A virus (HAV), hepatitis E virus (HEV), and hepatitis G virus 
(HGV). However, HBV and HCV are the most common inducers of hepatitis-related virus 
infections. People chronically infected with both hepatitis B and C present higher risk for 
developing HCC.
Besides hepatitis virus infection and fatty liver disease related or unrelated to alcohol con-
sumption, aflatoxin has been shown to increase the risk of developing HCC [28]. Aflatoxin is a 
family of fungus toxins that could be present at high levels in frequently consumed food such 
as nuts, grains, and spices that are not adequately selected or properly stored. Aflatoxin enters 
the food supply and can be found in animal and human-processed foods. Animals can pass 
aflatoxin derivative products into milk, eggs, and meat. Overweight and obesity constitute 
other independent risk factors for HCC. Therefore, in order to efficiently prevent hepatitis and 
HCC, raising awareness through general public education should be highly supported [29].
6. Treatment options for HCC
Currently, many options are available for the treatment of HCC [30]. Potentially curative 
treatments like surgical resection or liver transplantation might be possible for less advanced 
HCC. Minimally invasive surgical technologies continue to improve increasing its safety and 
applicability for oncologic liver surgery. Different surgical procedures, including advanced 
surgical technologies, are currently performed.
Unfortunately, tumor recurrence and metastasis frequently occur after resection and limit the 
overall survival. In patients with unresectable HCC and preserved liver function, transarterial 
chemoembolization (TACE) can prolong survival. However, TACE is rarely curative. More 
than half of patients with HCC continue to die secondary to liver failure from progressing 
cirrhosis. Current chemotherapy, interferon treatment, or alternative medicine only partially 
benefits patients with advanced disease. Therefore, novel treatments for liver cancer, particu-
larly advanced HCC, are in urgent need [31].
Since the introduction of sorafenib, a multikinase inhibitor that showed some benefits to HCC 
patients, other targeted and immune therapies emerged for the treatment of HCC. Currently, 
promising therapies for HCC are underway, including targeted therapy, immune checkpoint 
inhibitors, oncolytic viruses (OVs), and chimeric antigen receptor-redirected T cells (CAR-T 
cells). Combination strategies are also under investigation to promote further the treatment 
of advanced HCC [32].
7. Emergence of immune checkpoint inhibitors
HCC patients with advanced disease, not eligible for currently curative procedures, particu-
larly surgery or local interventions, were selected to test the efficacy of immune checkpoint 
inhibitors in clinical trials [11]. CTLA-4 blockade with tremelimumab showed a high promise 
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for controlling the tumor in patients with advanced HCC and HCV infections. This new 
therapeutic strategy opened the way for testing other immune checkpoint inhibitors, control-
ling other pathways such as PD-L1/PD-1. Furthermore evidences showing high expression of 
PD-L1/PD-1 in HCC patients support the use of PD-L1/PD-1 inhibitors. Indeed the result of 
PD-1 blockade with anti-PD-1 antibody (nivolumab) in a large phase II trial, regrouping HCC 
patients resistant to sorafenib is very promising [33, 34].
Although immunotherapy for HCC seems promising, important concerns regarding the 
selection of patients that could mostly benefit from this therapy are now under intensive 
investigation. In this regard, the mechanisms of resistance to immune checkpoint inhibitors 
and the identification of markers, predicting the response to immunotherapy need to be con-
sidered in selecting patients for treatment [35, 36].
In conclusion, promising results with immune blockade inhibitors have been currently pub-
lished in HCC clinical trials, using anti-CTLA-4 agent tremelimumab and anti-PD-1 agent 
nivolumab. We believe that in the near future, immune-based therapies and combination with 
chemotherapeutic agents will bring a paradigm shift for treatment of advanced HCC.
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